A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor Monotherapy in Patients with JAK Inhibitor-Naive Myelofibrosis and Moderate Thrombocytopenia (XPORT-MF-044)

被引：0
|
作者：
Scandura, Joseph M. [1 ]
Gerds, Aaron T. [2 ]
Ritchie, Ellen K. [3 ]
Wang, Xulong [4 ]
Kye, Steve [4 ]
Rampal, Raajit K. [5 ]
机构：
[1] Weill Cornell Med Coll, New York, NY USA
[2] Cleveland Clin, Cleveland, OH USA
[3] New York Presbyterian Hosp, Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA
[4] Karyopharm Therapeut, Newton, MA USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181720
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
634
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis (XPORT-MF-034)
    Maher, Keri
    Rampal, Raajit K.
    Bose, Prithviraj
    Podoltsev, Nikolai A.
    Harrison, Claire N.
    Hong, Junshik
    Wang, Xulong
    Chamoun, Kamal
    Mascarenhas, John
    BLOOD, 2023, 142
  • [2] Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naive myelofibrosis and moderate thrombocytopenia.
    Scandura, Joseph
    Gerds, Aaron Thomas
    Ritchie, Ellen K.
    Wang, Xulong
    Kye, Steve
    Rampal, Raajit
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with Myelofibrosis Refractory or Intolerant to JAK Inhibitors
    Tantravahi, Srinivas K.
    Kim, Soo Jin
    Sundar, Divya
    Patel, Ami B.
    Pomicter, Anthony D.
    Boucher, Kenneth M.
    Chamoun, Kamal
    Shah, Jatin
    Rets, Anton
    George, Tracy I.
    Prchal, Josef T.
    Deininger, Michael W.
    BLOOD, 2021, 138
  • [4] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
    Passamonti, Francesco
    Foran, James M.
    Tandra, Anand
    De Stefano, Valerio
    Fox, Maria Laura
    Mattour, Ahmad Hatem
    McMullin, Mary Frances
    Perkins, Andrew
    Rodriguez-Macias, Gabriela
    Sibai, Hassan
    Qin, Qin Q.
    Potluri, Jalaja
    How, Jonathan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naive Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study
    Mascarenhas, John
    Rampal, Raajit K.
    Grosicki, Sebastian
    Chraniuk, Dominik
    Abruzzese, Elisabetta
    Bose, Prithviraj
    Gerds, Aaron
    Vannucchi, Alessandro M.
    Palandri, Francesca
    Lee, Sung-Eun
    Gupta, Vikas
    Lucchesi, Alessandro
    Oh, Stephen T.
    Kuykendall, Andrew T.
    Patriarca, Andrea
    Alvarez-Larran, Alberto
    Mesa, Ruben
    Kiladjian, Jean-Jacques
    Talpaz, Moshe
    Lavie, David
    Harris, Morgan
    Kays, Sarah-Katharina
    Jegg, Anna Maria
    Wu, Manlei
    Brown, Barbara
    Harrison, Claire
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S416 - S417
  • [6] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi) Treatment-Naive Patients With Myelofibrosis: Updated Results and Subgroup Analyses from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S389 - S389
  • [7] Selinexor (SEL) plus ruxolitinib (RUX) in JAK inhibitor (JAKi) treatment-naive patients with myelofibrosis: Updated results from XPORT-MF-034
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naive Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification
    Tantravahi, Srinivas K.
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Prchal, Josef T.
    Wang, Xulong
    Chamoun, Kamal
    Walker, Christopher J.
    Taverna, Pietro
    Ali, Haris
    BLOOD, 2023, 142
  • [9] Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naive patients with myelofibrosis: Results of a phase II trial
    Zhang, Yi
    Zhou, Hu
    Jiang, Zhongxing
    Wu, Dengshu
    Zhuang, Junling
    Li, Wei
    Jiang, Qian
    Wang, Xiuli
    Huang, Jinwen
    Zhu, Huanling
    Yang, Linhua
    Du, Xin
    Li, Fei
    Xia, Ruixiang
    Zhang, Feng
    Hu, Jianda
    Li, Yan
    Hu, Yu
    Liu, Jing
    Jin, Chenghao
    Sun, Kai
    Zhou, Zeping
    Wu, Liqing
    Yu, Wenjuan
    Jin, Jie
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : 1510 - 1519
  • [10] CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
    Palandri, F.
    Mascarenhas, J.
    Harrison, C.
    Patriarca, A.
    Devos, T.
    Rampal, R.
    Vannucchi, A.
    Passamonti, F.
    Mead, A.
    Kremyanskaya, M.
    Somervaille, T.
    Wondergem, M.
    Hoffman, R.
    Luptakova, K.
    Wang, J.
    Colak, G.
    Shao, J.
    Bobba, S.
    Trojer, P.
    Verstovsek, S.
    Gupta, V.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 6
12345